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Introduction: Over the past decade, numerous non-skeletal diseases have been reported to be associated with
vitamin D deficiency including type2 diabetes mellitus (T2DM). Different studies provide evidence that vitamin D
may play a functional role in glucose tolerance through its effects on insulin secretion and insulin sensitivity. This
study evaluates the effects of vitamin D supplementation on insulin resistance in T2DM.
Method: Through a before-after study, 100 patients with T2DM, 30–70 years old, were recruited from an Arak
diabetes clinic as consecutive attenders. Participants were assessed for clinical and biochemistry. Serum insulin and,
25(OH)D concentration, and HOMA-IR was calculated. All measurements were performed at the beginning and the
end of the study. Patients received 50,000 unit of vitamin D3 orally per week for eight weeks, Statistical analysis was
made using SPSS17. The results were analyzed by descriptive tests, and a comparison between variables were
made using paired T-tests or Wilcoxon tests, as appropriate.
Results: 100 participants including 70 women (70%) and 30 men (30%) took part in the study. All results were
presented as Mean±SD, or medians of non-normally distributed.
24% of the participants were Vitamin D deficient {serum 25(OH)D ≤ 20 ng/ml(50 nmol/l)}.
Mean serum 25 (OH) D concentration was 43.03± 19.28 ng/ml (107.5±48.2 nmol/l).
The results at baseline and at the end, for FPG were 138.48±36.74 and 131.02±39 mg/dl (P=0.05), for insulin,
10.76±9.46 and 8.6±8.25 μIu/ml (P=0.028) and for HOMA-IR, 3.57±3.18 and 2.89±3.28 (P=0.008) respectively.
Conclusion: Our data showed significant improvements in serum FPG, insulin and in HOMA-IR after treatment with
vitamin D, suggested that vitamin D supplementation could reduce insulin resistance in T2DM.
Keywords: Diabetes, Insulin resistance, Vitamin DIntroduction
Over recent decades, numerous non-skeletal diseases
associated with vitamin D deficiency have been reported
including T2DM(type2 diabetes melitus) [1].
T2DM and vitamin D deficiency have risk factors in
common such as American-African race, obesity, aging
and low physical activity [2]. Also there are associations
of vitamin D deficiency with diseases such as osteopor-
osis, cardiovascular disease and metabolic syndrome
disorders diseases [3-5].
Some studies have shown a relationship between vita-
min D deficiency and T2DM [6]. Also some other stud-
ies have shown that vitamin D may play a functional* Correspondence: talaei@arakmu.ac.ir
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reproduction in any medium, provided the orrole on glucose tolerance through its effects on insulin
secretion and insulin sensitivity [7].
In comparison to healthy controls, subjects with
T2DM have significantly lower circulating concentration
of 25 (OH)D [8]. Also the prevalence of vitamin D defi-
ciency in women with T2DM is more common and also,
old men with vitamin D deficiency, secret higher insulin
after glucose intake [9,10].
Animal studies have shown that vitamin D is a basic
factor, necessary for normal insulin secretion [11,12].
Vitamin D reduces insulin resistance probably through
its effect on calcium and phosphorus metabolism and
through up regulation of the insulin receptor gene [13].
One study on 5,677 subjects with impaired glucose to-
lerance showed that vitamin D supplementation increased
insulin sensitivity by 54% [14]. Other studies also foundtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparison of biochemical characteristics(mean
± SD) in patients with diabetes type 2 before and after
treatment with vitamin D for 8 weeks
Variable Before treatment After treatment P-value
FPG(mg/dl) 138.48±36.74 131.02±39 0.05
(mmol/l) 7.6±2.04 7.27±2.16
Insulin(μIu/ml) 10.76±8.9 8.6±8.25 0.02
HOMA-IR 3.57±3.18 2.89±3.28 0.008
25(OH)D (ng/ml) 43.03±19.28 60.12±17.2 0.02
(nmol/l) 107.5±48.2 150.3±43
Table 3 Comparison of lipid profile in patients with
diabetes type 2 before and after treatment with vitamin
D(mean ± SD) for 8 weeks
Variable (mg/dl) Before treatment After treatment P-value
T-COL 191.1±32.2 180.2±31.0 0.3
TAG 234.4±73.3 201.0±65.1 0.2
LDL-C 109.5±26.4 103.0±23.2 0.5
HDL-C 42.5±8.1 38.2±7.2 0.3
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ity [15,16].
Another study on 126 healthy people showed that
there is a direct relation between insulin sensitivity and
25(OH)D level and that vitamin D deficiency had a
negative effect on β-cell function in pancreatic β-cells
[17]. One follow-up study, through 20 years on 4,843
patients with T2DM, showed that vitamin D intake was
associated with reduced prevalence of the T2DM [18].
T2DM is considered to develop from a state of increased
insulin resistance and β-cell dysfunction develope [19].
Studies on associations between insulin secretion and
serum 25 (OH)D have been inconsistent. We have eva-
luated the effects of vitamin D supplementation on insulin
resistance in subjects with T2DM.
Methods
Through a before and after matched, single blind study,
100 patients with T2DM aged 30–70 years old, were on a
diet (more intake of vegetables and fruits and limited use
of bread and rice that are usual foods in Iran) or taking
oral hypoglycemic agents(glibenclamide or repaglinide
+metformin or only metformin), reffered a diabetes clinic
at Arak medical university hospital, participated in the
study following invitation of consecutive clinical attenders.
The patients took part in the study for eight weeks. We
added vitamin D3 to their medication and recorded theirTable 2 The effects of vitamin D supplementation on FBS, ins
concentration (Drop line plot of vitamin D)
Variable Vitamin D <20 (n=20) Vita
Before after sig Before
FBS (mg/dl) 154±31.9 148±44.9 0.4 146±42.3
Insulin (μIu/ml) 10.16±9.2 9.1±6.1 0.6 8.7±10.1
HOMA_IR 3.6±1.2 3.05±1.6 0.6 3.2±4.05
Variable Vitamin D 40–60 (n=45)
before after sig
FBS(mg/dl) 131±34.6 120±35.6 0.02
Insulin(μIu/ml) 11.8±9.8 7.5±7 0.006
HOMA_IR 3.6±3.05 2.2v2.6 0.001demographic data and medication before and after supple-
mentation. During the trial, the subjects were instructed
not to change their diabetes drugs or diet.Participants
were assessed for weight, height, and BMI. FPG(Fasting
Plasma Glucose) and HbA1 were measured by enzymatic
and chromatographic methods using commercial kits
(Bio-system S.A and Human Germany) respectively. We
also measured serum creatinine, lipid profiles {TC(Total
Cholesterol), TAG(Triacylglyceride), HDL(High Density
Lipoprotein) and LDL(Low Density Lipoprotein)}, insulin,
Ca(Calcium), P(Phosphorous) and ALP(Alkaline Phospha-
tase). Serum 25(OH)D was measured by radioimmunoassay
(RIA) (kitsmanufactured by Biosource Europe SA, Belgium).
HOMA-IR (Hemostatic model assessment-Insulin resis-
tance) was calculated based on following formula [20]:
HOMA IR : FPG mmol=Lð Þ  Insulin μIu=mlð Þ
22:5
We also assessed liver function by measuring serum
concentration of AST (Aspartate Aminotransferase) and
ALT (Alanine Aminotransferase) to rule out liver disease
and major non alcoholic fatty disease of the liver as ex-
clusion criteria that might affect vitamin D metabolism.
Inclusion criteria were absence of hepatic, renal and
bone diseases, malignancy, any history of the use of
drugs such as insulin, anticonvulsants, calcium, vitamin
D and an HbA1c <8% for the last three months.
Written consent was obtained from all participants.
After baseline assessment all patients took 50,000 unitsulin and HOMA- IR at different baseline vitamin D
min D 20–30 (n=10) Vitamin D 30–45 (n=15)
after sig Before after sig
144±33.6 0.9 133±32.8 138±36.3 0.4
14.5±15.5 0.3 11.5±10.3 9.3±8.6 0.4






Table 4 Model for prediction of final FPG after treatment with vitamin D for 8 weeks in 100 patients with type
2diabetes





FBS-1 0.460 0.434 0.00 0.032
Vitamin D −0.394 −0.195 0.022
gender 16.488 0.195 0.020
HbA1C 7.024 0.184 0.031
Model: FBS2 = 0.46 × FBS1 0.39×Vitamin D+16.4×Gender +7.02×HbA1C+ 0.33.
FPG1: Baseline fasting plasma glucose.
Gender:male 1, Female 2.
Vitamin D: Baseline 25(OH)D.
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ment, all patients were visited and interviewed about
possible side effects, and to determine the degree of
compliance. After 2 months of treatment, all laboratory
tests and clinical evaluations were repeated as per the
initial visit. Patient compliance was assessed by tablet
counts at each visit in reports.
The Medical Ethics Committee of Arak medical univer-
sity approved the study protocol which complied with the
current version of the Declaration of Helsinki. Statistical
analysis was performed using Statistics Package for Social
Science (SPSS version 13, SPSS Inc., Chicago, IL, USA).
The Data were analyzed by descriptive tests such as mean,
SD(standard deviation), and SE (Standard Error) and K-S
(Kolmogorov-Smirnov) tests were performed to assess the
normality of the variables before further statistical ana-
lysis. All data in this study are presented as mean± SD.
The effects of Vitamin D supplementation on the variables
were analyzed by paired t test(for normally distributed) or
Wilcoxon test(for non-normally distributed). Step-wise lin-
ear regression analysis was used to provide models for
predicting of FPG, insulin and HOMA-IR, after vitamin D
supplementation. Baseline 25(OH)Dwas used in themodels.
Results
100 patients (70 women and 30 men) participated in this
study. The mean age of the participants was 54.1±11 yearsTable 5 Model for prediction of fasting serum Insulin after tre
diabetes for 8 weeks





Model: Insulin 2 = 0.25 × Insulin 1 0.08 × Vitamin D + 9.33.
Vitamin D: Baseline 25(OH)D.
Insulin1 : Baseline insulin.old. The mean weight of the patients at baseline was 70±12
and at the end was 71±05 kg that doesn,t have a meaning-
ful differences. 92% were controlled with oral hypo-
glycemic agents either as monotheraphy or in combination
theraphy (including glibenclamide, metformin and repag-
linide) and 8% were on alone diet. Mean 25 (OH) D con-
centration was 43.03±19.28 ng/ml(107.5±48.2 nmol/l) at
baseline and 24% of subjects at baseline were vitamin D
deficient based on 25 (OH) D<20 ng/ml(50 nmol/l). FPG
before and after treatment was normally distributed,so it
was analyzed by paired t test. But HOMA-IR and insulin
before and treatment were non-normally distributed, so
they were analyzed by Wilcoxon test. FPG and insulin con-
centration decreased significantly after treatment with vita-
min D3(P=0.05). Comparison of mean for HOMA-IR
before and after treatment with vitamin D showed a mean-
ingful reduction after supplementation (Table 1). We strati-
fied baseline serum 25(OH)D and reported the changes in
each variable for each stratum by plotting the changes in
each variable (Table 2).
Eight weeks of vitamin D supplementation did n,t
change mean serum concentration of TC,TG, HDL or
LDL cholesterol, vs baseline (Tables 3).
By using linear regression analysis,we suggest a model
for predicting FPG after supplementation with vitamin
D. We showed that the effect of vitamin D was to reduce
FPG 30% (Tables 4,5,6).atment with vitamin D in 100 patients with type 2







Table 6 Model for prediction of HOMA-IR after treatment with vitamin D





HOMA_IR_1 0.276 0.268 0.006 0.043
Vitamin D −0.035 −0.208 0.031
Model: HOMA-IR 2 = 0.27 × HOMA-IR 1 0.03 × Vitamin D + 3.43.
Vitamin D: Baseline 25(OH)D.
HOMA-IR-1: Baseline HOMA-IR.
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The main purpose of this study was to investigate the
effects of vitamin D supplementation on glucose homeo-
stasis. The results showed that vitamin D supplementa-
tion significantly decreased serum FPG,insulin and
HOMA-IR in patients with T2DM.
The role of basal serum FPG and vitamin D, sex, and
HbA1c in predicting FPG final was 36%. There was an
interesting finding. There was an inverse relation between
final FPG and basal 25(OH) D concentration. In other
words, higher serum basal 25(OH) D led to lower final
FPG. This means that who had a higher serum basal 25
(OH) D concentration benefited more of vitamin D intake
to lowering final FPG. This may be because of non-
skeletal effects of vitamin D which appears in higher vita-
min D concentration and the effects of lower vitamin D
concentration, are limited to the bone and muscle. Our
data showed that effects of vitamin D on insulin resistance
was significant when vitamin D concentration was 40–60
ng/ml(100–150 nmol/l) and in lower and upper vitamin D
concentration, it didn,t affect on insulin resistance.
Effects of vitamin D supplementation on glucose home-
ostasis have been shown in numerous studies. Our
findings are consistent with results of many other
published studies, in which the insulin resistance appears
to be decreased in T2DM patients who had received vita-
min D. For example,Inzucchi showed a 60% improvement
in insulin sensitivity by increased serum 25 (OH)D con-
centration from 10 to 30 ng/ml(25 to75nmol/l), by which
metformin or troglitazone were 54% and 13% respectively
[14]. Von Hurst (2009) showed that vitamin D supple-
mentation significantly improved insulin sensitivity and
insulin resistance [21]. Ken (2004) found an inverse rela-
tion between 25(OH) vitamin D concentration and FPG,
but a direct relation with insulin sensitivity [17].
As to these studies, our study shows that mean FPG
was significantly reduced after increased vitamin D in-
take. Monthly supplementation with 120,000 units of
vitamin D also improved insulin sensitivity [22]. Al-
though in contrast to some studies, there was a signifi-
cant reduction in HOMA-IR after taking vitamin D,
Witham foundout that vitamin D intake (at different
dosage) had no effects on insulin resistance or onHbA1c [23] as did Lind [24]. Nagpal reported that vita-
min D supplementation had no effect on mean of insulin
sensitivity but two years treatment with vitamin D did
improve HOMA-IR [25].
There are some mechanisms for the effects of vitamin
D: presence of vitamin D receptors on pancreatic β cells
[1], Vitamin D activating 1α hydroxylase is expressed in
pancreatic β cells [26], presence of vitamin D response
element in the insulin gene [27], presence of vitamin D re-
ceptor in skeletal muscle [28] and the fact that 1,25(OH)D
increases transcription of insulin receptor genes [13], and
also suppresses the renin gene reducing hyperglycemic-
induced increases in renin levels in pancreatic β cells and
blockade of renin-angiotensin activity has been proposed
as a novel target for diabetes treatment [29].
Protective effects of vitamin D on diabetes,maybe due
to well known effects of vitamin D such as its anti-
inflammatory properties, its effects on calcium and phos-
phorus metabolism and regulation of the insulin receptor
gene [13]. It seems that vitamin D increases in calcium
content of the cells, in turns leading to increased transport
of glucose into the muscle [30]. Vitamin D also regulates
nuclear PPAR (Peroxisome proliferative activated recep-
tor)that has an important role in the insulin sensitivity
[31]. vitamin D deficiency is associated with increases in
inflammation. Vitamin D attenuates the expression of
proinflammatory cytokines involved in insulin resistance
such as interleukins, IL-1, IL-6, TNF-a, also down regu-
lates NF-Kb (Nuclear factor) activity [32].
It would be useful, though to undertake further studies
to discover more about the mechanism and the effect of
vitamin D on both alpha and islet beta-cell function and
also on the mechanisms determining insulin resistance.
Some Iranian studies also showed that calcitriol [33],
vitamin D injection [34] and vitamin D intake could,nt
affect on diabetes and insulin resistance [35]. Although
some of them reported significant effects of vitamin D
on diabetes [36].
A limitation of our study is that we did not evaluate
the effects of placebo on FPG, insulin or HOMA-IR.
However, there are a few studies that didn’t use placebo,
evaluated the effects of vitamin D at different doses on
glucose homeostasis [21].
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It seems that vitamin D can improve diabetes control
and it is recommended that vitamin D supplementation
should be included in treatment of type 2 diabetes.
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